Chinese Journal of Pharmacovigilance ›› 2022, Vol. 19 ›› Issue (11): 1246-1249.
DOI: 10.19803/j.1672-8629.20210283

Previous Articles     Next Articles

153 linezolid-associated neurologic adverse reactions in patients with drug-resistant tuberculosis: a retrospective analysis

YANG Shaojie1, XIA Yuchao1, REN Pengfei2, WANG Jie2, CHEN Yu2,*   

  1. 1Department of Pharmacy, the Sixth People’s Hospital of Zhengzhou, Zhengzhou Henan 450015, China;
    2Department of Drug-resistant Tuberculosis, the Sixth People’s Hospital of Zhengzhou, Zhengzhou Henan 450015, China
  • Received:2021-03-31 Published:2022-11-17

Abstract: Objective To analyze the influencing factors and prognosis of linezolid (Lzd) associated neurologic adverse reactions in drug-resistant tuberculosis(DR-TB) patients. Methods The neurological adverse reactions caused by Lzd in DR-TB patients in the Sixth People’s Hospital of Zhengzhou between 2015 and 2020 were collected and analyzed. Results A total of 153 (27.18%) neurological adverse reactions occurred in 563 patients, 104 (67.93%) of which occurred within 3 to 9 months of use of LZD, mainly manifested as peripheral neuritis, optic neuritis, visual impairment, headache, insomnia and depression. Fifty-two cases (33.14%) were complicated with hypoproteinemia or malnutrition, and 28 (18.30%) with renal impairment. One hundred of these cases (65.36%) were discontinued with linezolid. Sixty-one cases (91.04%) of the central neurologic adverse reactions and optic neuritis were improved after symptomatic treatment or discontinuation of linezolid, but the prognosis of peripheral neuritis was poor. Conclusion Patients with long-term use of linezolid should be monitored for neurological adverse reactions. Early detection and prompt treatment have positive effects on prognosis.

Key words: linezolid, drug-resistant tuberculosis, neurologic, adverse drug reaction, peripheral neuritis, optic neuritis

CLC Number: